PFMCON: Pelvic Floor Consciousness

Sponsor
University of Alcala (Other)
Overall Status
Unknown status
CT.gov ID
NCT04334798
Collaborator
(none)
120
3
4
35
40
1.1

Study Details

Study Description

Brief Summary

The purpose of the study is to compare the efficacy of different modalities ofof motor learning of pelvic floor muscle contraction in women with pelvic floor dysfunctions, considering the efficacy of the treatment as improving the specific quality of life related to pelvic floor dysfunctions and improvement of the muscular properties of the pelvic floor muscles.

Condition or Disease Intervention/Treatment Phase
  • Other: Active exercises of the pelvic floor muscles & Electrostimulation & Biofeedback
  • Other: Active exercises of the pelvic floor muscles & Biofeedback
  • Other: Active exercises of the pelvic floor muscles & Transabdominal US Biofeedback
  • Other: Active exercises of the pelvic floor muscles & Electrostimulation &Transabdominal US Biofeedback
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Different Modalities of Motor Learning of Pelvic Floor Muscle Contraction in Women With Pelvic Floor Dysfunction: Randomized Controlled Trial
Actual Study Start Date :
Jan 10, 2019
Anticipated Primary Completion Date :
Oct 20, 2021
Anticipated Study Completion Date :
Dec 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: PFM&electro&BFB

An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the pelvic floor muscles (PFM) will be performed using intravaginal palpation and electrostimulation, together with biofeedback (BFB).

Other: Active exercises of the pelvic floor muscles & Electrostimulation & Biofeedback
See information included in arm/group descriptions.

Experimental: PFM&BFB

An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with biofeedback (BFB).

Other: Active exercises of the pelvic floor muscles & Biofeedback
See information included in arm/group descriptions.

Experimental: PFM&electro&transabdominal US

An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation and electrostimulation, together with transabdominal ultrasound biofeedback (BFB).

Other: Active exercises of the pelvic floor muscles & Electrostimulation &Transabdominal US Biofeedback
See information included in arm/group descriptions.

Experimental: PFM&transabdominal US

An educational program (anatomical and physiological explanation of the abdomen-pelvic cavity (perineal organs, bone, ligament and muscle structures of the entire abdomen-pelvic cavity; knack) will be implemented, and active exercises of the PFM will be performed using intravaginal palpation together with transabdominal ultrasound biofeedback (BFB).

Other: Active exercises of the pelvic floor muscles & Transabdominal US Biofeedback
See information included in arm/group descriptions.

Outcome Measures

Primary Outcome Measures

  1. Change in life impact of pelvic floor dysfunction [5 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 months, 6 months and 12 months after the intervention.]

    It will be assessed by the Pelvic Floor Impact Questionnaire-7 (PFIQ-7) Spanish version. The PFIQ-7 consists of 3 scales of 7 questions each taken from the Urinary Impact Questionnaire, the Pelvic Organ Prolapse Impact Questionnaire, and the Colorectal-Anal Impact Questionnaire. The 3 scales are scored from 0 (least impact) to 100 (greatest impact) and an overall summary score (0 to 300).

  2. Change in symptoms and quality of life [5 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 months, 6 months and 12 months after the intervention.]

    It will be assessed by the Pelvic Floor Distress Inventory-20 (PFDI-20) Spanish version that is both a symptom inventory and a measure of the degree of bother and distress caused by pelvic floor symptoms. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300 and the higher the score, the worse quality of life. The 3 scales include questions taken from the following widely used outcome measures: Urinary Distress Inventory - 6 questions, Pelvic Organ Prolapse (POP) Distress Inventory - 6 questions, and Colorectal-Anal Distress Inventory - 8 questions collecting data about Urinary Incontinence (UI), POP and colorectal and anal symptoms.

Secondary Outcome Measures

  1. Change in pelvic floor muscle strength [5 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 months, 6 months and 12 months after the intervention.]

    It will be measured by Modified Oxford Scale to rate pelvic floor muscle contraction on a scale of 0-5: 0 = no contraction; 1 = minor muscle; 'flicker'; 2 = weak muscle; contraction; 3 = moderate muscle contraction; 4 = good muscle contraction and 5 = strong muscle contraction.

  2. Change in pelvic floor muscle strength [5 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 months, 6 months and 12 months after the intervention.]

    It will be measured by dynamometry (measured in GRAMS).

  3. Change in pelvic floor muscle passive tone [5 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 months, 6 months and 12 months after the intervention.]

    It will be measured by dynamometry (measured in GRAMS).

  4. Change in the displacement of the base of the bladder during voluntary contraction of the pelvic floor [5 assessments to evaluate change from baseline: at baseline, after the intervention period (2 months from baseline), 3 months, 6 months and 12 months after the intervention.]

    It will be measured by Ultrasound

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women diagnosed with pelvic floor dysfunction by their doctor.

  • Women who are unable to voluntarily contract the pelvic floor muscles, quantified by the Modified Oxford Score by a score less than or equal to 2.

Exclusion Criteria:
  • Women who are pregnant or women who have had a vaginal or caesarean birth in the past six months.

  • Women whose PFD is severe, and the first indication is surgical (POP-Q grade III-IV prolapses).

  • Women with pain in the pelvic-perineal region of 3 cm in the visual analog scale, where a score of 0 cm means no pain, and a score of 10 cm, the maximum pain that the participant can imagine.

  • Women who have received pelvic floor physiotherapy treatment in the last 12 months.

  • Women with any pathology that may affect the treatment (neurological, gynecological or urological), or with recurrent urinary infection or hematuria.

  • Women with cognitive limitations to understand the information, answer the questionnaires, consent and / or participate in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Physiotherapy in women´s health research group. University of Alcalà Alcalà de Henares Madrid Spain 28871
2 María Torres-Lacomba Alcalá de Henares Madrid Spain 28005
3 University of Alcalá. FPSM research group. HUPA Alcalá de Henares Madrid Spain 28805

Sponsors and Collaborators

  • University of Alcala

Investigators

  • Principal Investigator: María Torres-Lacomba, PhD, University of Alcalá

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maria Torres Lacomba, Principal investigator & Professor, University of Alcala
ClinicalTrials.gov Identifier:
NCT04334798
Other Study ID Numbers:
  • OE14/2020
First Posted:
Apr 6, 2020
Last Update Posted:
Apr 7, 2020
Last Verified:
Apr 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Maria Torres Lacomba, Principal investigator & Professor, University of Alcala
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2020